Research News Hubb
Advertisement Banner
  • Home
  • Global Trends
  • Market Research
  • Contact
No Result
View All Result
  • Home
  • Global Trends
  • Market Research
  • Contact
No Result
View All Result
Research News Hubb
No Result
View All Result
Home Global Trends

Study demonstrates potential of immunotherapy targeting skin cancer

admin by admin
May 2, 2023
in Global Trends



A new type of immunotherapy has potential for fighting the most aggressive form of skin cancer, finds research.

A study by researchers at King’s College London and St Thomas’ and Guy’s NHS Foundation Trust, investigates the potential of a novel antibody to target and treat melanomas. The findings show that the antibody triggers the immune response to fight cancer and delays melanoma growth in mice.

Clinically, malignant melanoma is the most threatening type of skin cancer with low survival rates for half of patients within five-years of diagnosis. Although there has been significant advancement in developing immunotherapies, the tumors in many patients do not respond. This drug could serve to benefit patients with melanoma who do not respond to currently available treatment.

Many immunotherapies currently used in cancer treatment belong to IgG antibody type. However, researchers at Guy’s and St Thomas’ and King’s College London have created IgE antibody which can use the patient’s own immune system to invade cancer differently.

The team of researchers developed IgE antibody that distinctly serves as an indicator on the exterior of human melanoma cells. These cells known as chondroitin sulfate proteoglycan 4 (CSPG4) are present in up to 70% of melanomas. Meanwhile, existing immunotherapies broadly draw upon the immune system’s defences; on the other hand, this novel antibody is designed to target immune responses specifically toward melanoma cells.

The researchers demonstrated that chondroitin sulfate proteoglycan IgE could join with and activate immune cells present in the blood of melanoma patient to destroy melanoma cancer cells. CSPG4 IgE treatment delayed cancer growth in mice injected with human immune cells. An allergy test carried out on patient revealed that CSPG4 IgE refrained from activating while blood cells called basophils, suggesting the therapy may be safe to be administered

Like this:

Like Loading…




Source link

Previous Post

Industry CRM Is A Clear Choice In Economic Downturns

Next Post

The Right Way To Set CX Metrics Goals

Next Post

The Right Way To Set CX Metrics Goals

Recommended

Forget Quiet Quitting — Tech Whistleblowers Go Out With A Bang

9 months ago

The Edge Of The Age Of AI

2 months ago

U.S. Beverage Market Overview: Key Categories to Watch

9 months ago

Twitter Needs Advertisers, But Advertisers Don’t Need Twitter

5 months ago

No, March Isn’t Toilet Paper And Pasta Month Buyer insight data

5 months ago
[PODCAST] Why sustainability should be at the top of ev

[PODCAST] Why sustainability should be at the top of ev

9 months ago

© Research News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Global Trends
  • Market Research
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Global Trends
  • Market Research
  • Contact

© 2022 Research News Hubb All rights reserved.